Viridian Therapeutics, Inc. ownership filing shows Bellevue Group and its wholly owned subsidiary Bellevue Asset Management AG report 6,726,144 shares of Common Stock, representing 6.6% of the class as of 03/31/2026. The percentage is calculated using 102,458,094 shares deemed outstanding.
The statement is filed jointly by Bellevue Group AG and BAM AG, with shared voting and dispositive power over the disclosed shares.
Positive
None.
Negative
None.
Insights
Bellevue reports a 6.6% stake via shared voting/dispositive power.
Bellevue Group AG and Bellevue Asset Management AG disclose beneficial ownership of 6,726,144 shares, with both shared voting and shared dispositive power over those shares. The filing follows Schedule 13G reporting norms for passive/beneficial holders.
Impact depends on whether the position is passive; subsequent filings could clarify intent or changes in voting power.
Filing is a joint Schedule 13G with subsidiary attribution; signatures included.
The schedule identifies BAM AG as a wholly‑owned subsidiary of Bellevue and lists shared control metrics (shared voting and dispositive power: 6,726,144). Signatures by Bellevue representatives are provided with a 05/15/2026 signing date.
Watch for any future amendments or a Schedule 13D if the holder's intent changes.
Key Figures
Shares beneficially owned:6,726,144 sharesPercent of class:6.6%Shares deemed outstanding:102,458,094 shares
3 metrics
Shares beneficially owned6,726,144 sharesAmount reported by Bellevue/BAM AG
Percent of class6.6%Calculated based on 102,458,094 shares deemed outstanding
Shares deemed outstanding102,458,094 sharesUsed to calculate the 6.6% figure
Key Terms
Schedule 13G, Beneficially owned, Shared dispositive power
3 terms
Schedule 13Gregulatory
"This statement is filed jointly by Bellevue and BAM AG."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially ownedfinancial
"Amount beneficially owned: 6,726,144"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Bellevue Group reports beneficial ownership of 6,726,144 shares (6.6%). This percentage uses 102,458,094 shares deemed outstanding to calculate the ownership stake as stated in the filing.
Which entities filed the Schedule 13G for VRDN?
The filing is made jointly by Bellevue Group AG and its wholly‑owned subsidiary Bellevue Asset Management AG (BAM AG). The exhibit states BAM AG is a wholly‑owned subsidiary of Bellevue.
What voting and dispositive powers are reported by Bellevue for VRDN shares?
Bellevue reports shared voting power of 6,726,144 shares and shared dispositive power of 6,726,144. Sole voting and sole dispositive powers are reported as zero.
When was the ownership amount and filing signed?
The ownership figures are dated 03/31/2026 and the Schedule 13G signatures are dated 05/15/2026. Signatories include Bellevue officers and BAM AG representatives.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Viridian Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
92790C104
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
92790C104
1
Names of Reporting Persons
Bellevue Group AG
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,726,144.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,726,144.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,726,144.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.6 %
12
Type of Reporting Person (See Instructions)
HC, CO
Comment for Type of Reporting Person: The percentage set forth in Row 11 is calculated based on 102,458,094 shares of Common Stock deemed outstanding.
SCHEDULE 13G
CUSIP Number(s):
92790C104
1
Names of Reporting Persons
Bellevue Asset Management AG
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,726,144.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,726,144.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,726,144.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.6 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: The percentage set forth in Row 11 is calculated based on 102,458,094 shares of Common Stock deemed outstanding.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Viridian Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
221 Crescent Street, Suite 103A, Waltham, MA 02453
Item 2.
(a)
Name of person filing:
Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG").
(b)
Address or principal business office or, if none, residence:
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
6,726,144
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
